🇺🇸 FDA

Company profile · Sponsor

First

First Tracks Biotherapeutics

TRAX · NYSE pharma SAN DIEGO, CA, USA
Pipeline
24
Drugs
0
Patents
8

Quick answer

First (TRAX) is a pharma company. headquartered in SAN DIEGO, CA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker TRAX
Exchange NYSE
Company type pharma
Headquarters SAN DIEGO, CA, USA
SEC CIK 0002091349

Pipeline (24)

Search pipeline →

  1. 2 cycles induction chemotherapy

    First

    Locally Advanced Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  2. 20 mg sildenafil citrate by mouth

    First

    Pulmonary Hypertension

    phase 3 small molecule active

    1 trial

  3. 3-N-butylphthalide

    First

    Multiple System Atrophy

    phase 3 small molecule active

    1 trial

  4. 6-month course of antiandrogen drugs

    First

    Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

    phase 3 small molecule active

    1 trial

  5. AZVUDINE

    First

    Chronic Hepatitis B

    phase 3 small molecule active

    1 trial

  6. Acetazolamide Levamisole

    First

    HCC

    phase 3 small molecule active

    1 trial

  7. Aerobic Exercise

    First

    Primary Hypertension

    phase 3 other active

    1 trial

  8. Alirocumab

    First

    Intracranial Atherosclerosis

    phase 3 small molecule active

    1 trial

  9. Amlodipine

    First

    Sleep Apnea Syndrome

    phase 3 small molecule active

    1 trial

  10. Azacitidine Combined With Venetoclax and ATRA group

    First

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  11. Azathioprine

    First

    Myasthenia Gravis

    phase 3 small molecule completed

    1 trial

  12. Bedaquiline (B)

    First

    Pulmonary Tuberculosis

    phase 3 small molecule active

    1 trial

  13. Botulinum Toxin type A (intradermal / submucosal injection at pain area)

    First

    Trigeminal Neuralgia

    phase 3 small molecule active

    1 trial

  14. Busulfan (BU)

    First

    Primary Central Nervous System Lymphoma

    phase 3 small molecule active

    1 trial

  15. Camrelizumab

    First

    Esophageal Cancer

    phase 3 small molecule active

    2 trials

  16. Capecitabine monotherapy

    First

    Gastric Cancer

    phase 3 small molecule active

    1 trial

  17. Capecitabine(Aibin)

    First

    Stage III Esophageal Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  18. Chemotherapy

    First

    Acute Lymphoblastic Leukemia

    phase 3 small molecule completed

    1 trial

  19. Chemotherapy

    First

    Endometrial Cancer

    phase 3 small molecule active

    1 trial

  20. Clamp-Crushing technique

    First

    Hepatobiliary Disease

    phase 3 other completed

    1 trial

  21. Continuous Gastrocnemius plane block with ropivacaine

    First

    Foot Ankle Injuries

    phase 3 small molecule active

    1 trial

  22. Crystalline cellulose simple occlusive dressing

    First

    Split-thickness Skin Graft Donor Sites

    phase 3 other completed

    1 trial

  23. Cytarabine

    First

    Leukemia

    phase 3 small molecule active

    1 trial

  24. Decitabine

    First

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

Patents (8)

Search patents →

  1. US 12357666

    Traditional Chinese herbal plant composition for improving symptoms of liver cancer patients and compatibility method thereof

    Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12228572

    Enhanced expression of polo-like kinase 3 (PLK3) in human immunodeficiency virus (HIV)-infected cells

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12220446

    Use of upstream open reading frame 45aa-uORF nucleotide sequence of PTEN gene and polypeptide coded by 45aa-uORF

    Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12090156

    Application of CB-839 in preparation of drug for inhibiting corneal neovascularization (CNV)

    Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12076443

    Preparation method of nanozyme composite-based hybrid hydrogel eye drop

    Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12016950

    Devices and methods for treating ear pain

    Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11992555

    Solid solution compositions and use in chronic inflammation

    Expires Mon May 23 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11980602

    Cannabinoid prodrug compounds

    Expires Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is First?

First (TRAX) is a pharma company. headquartered in SAN DIEGO, CA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does First sponsor?

We track 24 ClinicalTrials.gov-linked programs for First, including 2 cycles induction chemotherapy and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does First company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.